<DOC>
	<DOCNO>NCT02113033</DOCNO>
	<brief_summary>The purpose VANGUARD study demonstrate safety Vagal Nerve Stimulation treatment congestive heart failure reduce ejection fraction , report secondary measure efficacy .</brief_summary>
	<brief_title>VAgal Nerve Stimulation : safeGUARDing Heart Failure Patients</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Left ventricular dysfunction ischemic idiopathic dilate cardiomyopathy etiology , characterize LVEF &lt; 40 % 2 . Chronic heart failure symptom characterize NYHA functional class II III time enrollment despite optimal drug regimen 3 . Optimal drug regimen define current European guideline 4 . Sinus rhythm , spontaneous heart rate â‰¥ 60bpm time enrollment 5 . Signed date informed consent Main Patient implant eligible cardiac pace per current guideline Risk neck surgery electrode zone within year enrollment Patient right carotid artery stenosis Symptomatic hypotension History peptic ulcer disease upper gastrointestinal bleeding Asthma , severe COPD , severe restrictive lung disease Advanced Diabetes Mellitus Recent acute myocardial infarction , coronary artery surgery revascularization ( already plan ) Recent cerebrovascular event Significant valvulopathy Advanced Renal failure Previous heart transplant current LVAD device therapy Life expectancy &lt; 1 year noncardiac cause Patient include another clinical study could confound result study Inability understand purpose study perform procedure study Unavailability schedule followup Age le 18 year guardianship Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>